Analysts Anticipate Neovasc Inc (NASDAQ:NVCN) Will Announce Earnings of -$0.89 Per Share

Analysts expect Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) to report earnings per share of ($0.89) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Neovasc’s earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($1.14). Neovasc reported earnings of ($1.50) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 40.7%. The firm is scheduled to issue its next earnings results on Thursday, March 19th.

On average, analysts expect that Neovasc will report full-year earnings of ($3.87) per share for the current fiscal year, with EPS estimates ranging from ($4.39) to ($3.35). For the next fiscal year, analysts forecast that the company will post earnings of ($2.45) per share, with EPS estimates ranging from ($3.54) to ($1.36). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Neovasc.

Several research firms have weighed in on NVCN. HC Wainwright set a $9.00 target price on shares of Neovasc and gave the stock a “buy” rating in a report on Monday, November 4th. Zacks Investment Research raised shares of Neovasc from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Wednesday, November 13th.

Shares of NASDAQ NVCN opened at $2.96 on Thursday. The stock has a market cap of $22.00 million, a P/E ratio of -0.11 and a beta of 1.43. The firm has a 50 day moving average price of $3.33 and a 200 day moving average price of $2.77. Neovasc has a 52-week low of $2.34 and a 52-week high of $11.00.

A number of hedge funds have recently bought and sold shares of the business. Bank of Montreal Can grew its stake in Neovasc by 72.7% in the second quarter. Bank of Montreal Can now owns 51,807 shares of the medical equipment provider’s stock valued at $250,000 after acquiring an additional 21,807 shares during the period. Citadel Advisors LLC bought a new stake in shares of Neovasc in the second quarter worth about $36,000. Finally, Magnetar Financial LLC increased its holdings in shares of Neovasc by 325.3% in the second quarter. Magnetar Financial LLC now owns 4,809,269 shares of the medical equipment provider’s stock worth $2,322,000 after acquiring an additional 3,678,404 shares in the last quarter. Hedge funds and other institutional investors own 15.04% of the company’s stock.

About Neovasc

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Featured Article: Hold Rating

Get a free copy of the Zacks research report on Neovasc (NVCN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Neovasc (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit